Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007253 · ClinicalTrials.gov registry record · Phase 4
Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01007253 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 21 participants.
The verdict
NCT01007253, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
People who have hayfever or allergic rhinitis often complain about eye symptoms associated with their nasal symptoms. How people with hayfever develop eye symptoms is not clear. The purpose of this study is to better understand the generation of eye symptoms in patients with allergic rhinitis. We have previously shown that placing the substance that subjects are allergic to in their nose causes both nose and eye symptoms. This can be explain by a parasympathetic neurogenic reflex from the nose to the eye. Such a reflex would readily explain the tearing and watery eye symptoms, but does not explain the itch. In this study, we are going to address one possible explanation for the itch; does an axonal neurogenic reflex stimulate mast cells in the eye to release histamine, which then causes the itch? We will do this by placing an antihistamine drop in the eye and challenge the nose with allergen. We will also attempt to demonstrate that mast activation isn't effected by blocking the initiating of the reflex with a nasal steroid, as done in our previous study, and showing that the addition of an antihistamine does not add to the reduction of symptoms.
Interventions
- DRUG fluticasone furoate (FF)
- DRUG PL nasal spray
- DRUG PL eye drops
- DRUG olopatadine (OLO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01007253
The ClinicalTrials.gov registry entry for NCT01007253 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluticasone furoate (FF) is the first listed.
NCT01007253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01007253 about?
NCT01007253 is a clinical study titled "Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms". People who have hayfever or allergic rhinitis often complain about eye symptoms associated with their nasal symptoms. How people with hayfever develop eye symptoms is not clear. The purpose of this study is to better understand the generation of eye symptoms in patients with allergic rhinitis. We ha...
What is the current status of trial NCT01007253?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2009-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01007253?
The interventions under investigation include: fluticasone furoate (FF) (DRUG), PL nasal spray (DRUG), PL eye drops (DRUG), olopatadine (OLO) (DRUG).
Who is sponsoring clinical trial NCT01007253?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.